Beth Israel Deaconess Medical Center

HARVARD MEDICAL SCHOOL TEACHING HOSPITAL

Topline Results From BOND-003 Cohort P: A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High-Risk, Papillary Only (HG Ta/T1), BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Timothy N. Clinton, MD

Presented at the New England Section of the American Urological Association Annual Meeting
October 23, 2026

For individual reference only. The information accessed through this QR code is intended solely for individual reference and should not be altered, modified, or reproduced in any way.

Disclosures

- Clinical investigator: CG Oncology, Protara Therapeutics
- Consulting: Intuitive Surgical, Lily, Protara, Olympus

Oncolytic Immunotherapy: Cretostimogene Grenadenorepvec's Dual Mechanism of Action



Significant Unmet Need for BCG-UR Papillary (HG Ta/T1) NMIBC

- FDA-approved treatment options for BCG-UR HG Ta/T1 NMIBC remain limited compared with those for CIS-containing disease
- Patients commonly present with HG Ta/T1 NMIBC[1-2]
- **Benchmarks reported from recent meta-analysis for BCG-UR HG Ta/T1 NMIBC[3]**
  - 73% at 3 mo
  - 58% at 6 mo
  - 48% at 12 mo

DFS/HG-RFS	Pembrolizumab [5]	Nadofaragene [6,7]	N-803+BCG [8,9]	TAR-200 [10]
3 months, % (95% CI)	87.7 (80.7-92.3)	72.9 (58.2-84.7)	Not Reported	Not Reported
6 months, % (95% CI)	53.1 (44.1-61.2)	62.5 (47.4-76.0)	Not Reported	85.3 (71.6-92.7)
9 months, % (95% CI)	Not Reported	58.3 (43.2–72.4)	Not Reported	81.1 (66.7-89.7)
12 months, % (95% CI)	43.5 (34.9-51.9)	43.8 (29.5-58.8)	55.4 (42.0-66.8)	70.2 (51.6-82.8)
24 months, % (95% CI)	34.9 (26.4-43.4)	33.3 (20.4-48.4)	48.3 (34.5-60.7)	Not Reported

There remains a significant unmet need for clinically effective and well-tolerated bladder-sparing treatment options for the BCG-UR papillary-only NMIBC population

BCG- Bacillus Calmette Guerin; CIS +/- Ta/T1- Carcinoma in situ, with or without Ta/T1; NMIBC- Non-Muscle Invasive Bladder Cancer; 1 Nielsen et al 2014. *Cancer*. 2014 2. Taylor J. Long Term Outcomes of Bladder Sparing Therapy Compared to Upfront Radical Cystectomy in BCG Unresponsive NMIBC in an International Cohort . Presented at: SUO 2023. 3.Rose KM, et al. *SIUJ*. 2022;3(5):333-339 5. Necchi A, et al. *Lancet Oncology*. 2024; 25(6):720-730. 6. Boorjian S, et al. *Lancet Oncology*. 2021; 22(1):107-117. 7. Narayan VM, et al. *J Urol*. 2024;212(1):74-86. 8. Chamie K, et al. *NEJM Evid*. 2023; 2(1):EVIDoa2200167. 9. Daneshmand S, et al. *JCO*. 2025. doi: 10.1200/JCO-25-01651.

BOND-003 Cohort P: Papillary Only (HG Ta/T1), BCG-UR, HR-NMIBC

Cohort C (N=112)
- Age ≥ 18 yo
- ECOG PS 0-2
- Pathologically confirmed BCG-UR HR-NMIBC with CIS +/- papillary disease

Primary Endpoint
CR at any time

Secondary Endpoints
Duration of Response
CFS, RFS, PFS

Cohort P (N=56)
- Age ≥ 18 yo
- Pathologically confirmed HR BCG-UR NMIBC HG Ta/T1 (Without CIS)
- Completely resected prior to treatment

Primary Endpoint
HG-EFS

Secondary Endpoints
RFS, PFS, CFS, CSS



BCG: Bacillus Calmette-Guérin; BCG-UR: BCG-unresponsive; CFS: cystectomy-free survival; CIS: carcinoma in situ; CR: complete response; CSS: cancer-specific survival; ECOG PS: Eastern Cooperative Oncology Group performance status; HG: high grade; HG-EFS: high-grade event-free survival; HR: high risk; NMIBC: non-muscle invasive bladder cancer; PFS: progression-free survival; RFS: recurrence-free survival; Ta/T1: tumor stage (non-invasive papillary / lamina propria-invasive)

Patient Demographics & Baseline Characteristics

Patients in Safety Dataset	N=56	%
Gender		
Male	44	78.6
Female	12	21.4
Age (Years)		
Mean (SD)	71.6 (9.3)	
Median (Range)	74.0 (45-87)	
Age (Categories)		
< 65	13	23.2
≥ 65 and < 75	18	32.1
≥75	25	44.6
ECOG PS		
ECOG PS 0	48	85.7
ECOG PS 1	8	14.3
HR NMIBC T-Stage at Study Entry		
HG Ta	37	66.1
HG T1	19	33.9
BCG History: No. of Prior Instillations		
Median (Range)	9.0 (5 – 21)	

- Majority of patients are:
  - Male (78.6%)
  - White (87.5%)
  - > 65 years (75%)
- 96.4% of patients in US
- **High-Risk population enrolled, with 33.9% HG T1 at baseline**

Topline Results: BOND-003 Cohort P HR, Papillary-Only (HG Ta/T1) BCG-Unresponsive NMIBC

- Median follow-up: 6.0 months
- 8 patients were re-induced at 3 months
- Consistent and high HG-EFS
  - HG-Ta:
    - 92.8% (3 mo)
    - 75.9% (6 mo)
    - 75.9% (9 mo)
  - HG-T1:
    - 100% (3 mo)
    - 100% (6 mo)
    - 87.5% (9 mo)
- No patients underwent RC
- No progression to MIBC*



HR= High-Risk; HG-RFS= High-Grade Recurrence-Free Survival; NMIBC= Non-Muscle Invasive Bladder Cancer; RC= Radical Cystectomy
01SEP2025 data cut off. Censored patients include 5 patients pending efficacy assessments.
HG-EFS time from first study treatment (first re-induction dose) to high-grade recurrence, progression, death, or censoring.
* 1 pt progressed to metastatic urothelial carcinoma despite clinical complete response in the bladder.

Consistent, Favorable and Well-Tolerated Safety Profile

Preferred Term (MedDRA v.26.1)	Cretostimogene (n=56)	
	Any Grade (%)	Grade ≥ 3
Patients with ≥ 1 TRAE	40 (71.4%)	0 (0)
Treatment-Related AE reported in > 10% patients		
Bladder Spasm	26 (46.4%)	0 (0)
Dysuria	22 (39.3%)	0 (0)
Pollakiuria	14 (25.0%)	0 (0)
Urgency	11 (19.6%)	0 (0)

- Most AEs were Grade 1-2
- **0% Grade ≥ 3 TRAEs, Serious TRAE, deaths**
- **No dose delays, missed doses due to TRAEs**
- **No treatment related discontinuations**
- 98.2% received all protocol defined treatments

01SEP2025 data cut off
AE: adverse event; TEAE: treatment-emergent adverse event; TRAE: treatment-related adverse event.

BOND-003 Cohort P: Conclusions

- Topline results with cretostimogene in BOND-003 Cohort P consistently demonstrate
  - Strong HG-EFS at 3, 6, and 9 mo
  - Responses maintained across HGTa and higher-risk, HGT1, populations
  - Well-tolerated safety profile
- Longer-term treatment and follow up ongoing

THANK YOU

All Bladder Cancer Patients and Their Families

Study Coordinators and Nurses

Key Collaborators

Siamak Daneshmand USC, Los Angeles, CA

Timothy Lyon, Mayo Clinic, Jacksonville, FL

Ankeet Shah, Duke, Durham, NC

Trinity Bivalacqua, UPenn, Philadelphia, PA

Amy Luckenbaugh, Vanderbilt, Nashville, TN

Colin P.N. Dinney, URMC, Rochester, NY

Mark Tyson, Mayo Clinic, Phoenix, AZ

CG Oncology

Jee-Hyun Kim

Pat Keegan

Ana Shermolovych

Rob Svatek

Shelja Patel

Sarah Hohl

Vijay Kasturi

For individual reference only. The information accessed through this QR code is intended solely for individual reference and should not be altered, modified, or reproduced in any way.